At the news
? NEUTRALIMPACT 4/10 8-K filed Sep 3, 2026 at 11:45 ET
GT Biopharma filed a Certificate of Amendment to effect a 1-for-25 reverse stock split and reduce authorized shares from 265M to 26.5M, effective September 8, 2026. The company also eliminated 11 series of preferred stock (none outstanding except Series C which was converted). This is a capital structure cleanup and Nasdaq compliance action for a micro-cap biotech with a $13M market cap, not a fundamental business event.
- 1-for-25 reverse stock split effective September 8, 2026 at 12:01 a.m. ET
- Pre-split shares: ~45,109,497 → post-split: ~1,804,379
- Authorized shares reduced from 265,000,000 to 26,500,000 (25M common + 1.5M preferred)
- 11 series of preferred stock eliminated via Certificates of Elimination (none were outstanding)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access